Clinical Trials Detail

Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Objective
CategoryInformation
Study #: A151216 - Alchemist
Anatomic Site: Lung
Histology:
  • Non-Small Cell Lung Cancer (NSCLC)
  • Non-Small Cell Lung Carcinoma
Mutation: EGFR exon 19 deletion; L858R mutation
Stage: NSCLC:
  • Stage IB
  • Stage IIA
  • Stage IIB
Carcinoma: Stage IIA
Treatment Phase: Previously registered to A151216 with an EGFR exon 19 deletion or L858R mutation, have complete recovery from surgery and standard post-operative therapy.
Location:
Study Link: https://clinicaltrials.gov/ct2/show/NCT02193282?term=A081105&rank=2

Clinical Trial Categories

  • Lung